BridgeMD
New treatment option for Healthy Subjects
Official title Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)
ClinicalTrials.gov ID: NCT06682819
What this study is testing
- What it's testing
- Leber hereditary optic neuropathy (LHON), due to mitochondrial DNA (mtDNA) mutations, is responsible for profound visual impairment. However, there is evidence that optic nerve damage begins before vision declines.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60. Healthy volunteers may be eligible.
You may be able to join if
- Patient carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or 14484) with normal visual acuity and who has never had optic neuropathy, or...
- Patient agreeing to undergo an OCT;
- Patient agreeing to sign the informed consent;
- Patient affiliated to French social protection (Primary Health Insurance Fund, CMU, etc.) or European social protection.
You likely can't join if
- Patient with or having had optic neuropathy regardless of its etiology
- Patient with glaucoma regardless of its etiology;
- Patient not wanting to undergo OCT;
- Patient not wanting to sign the informed consent;
- Patient not affiliated with French social protection (Primary Health Insurance Fund, CMU, etc.) or European.
- Patients less than 18 years old or over 60 years old
See the full eligibility criteria
- Patient carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or 14484) with normal visual acuity and who has never had optic neuropathy, or Patient not carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or...
- Patient agreeing to undergo an OCT;
- Patient agreeing to sign the informed consent;
- Patient affiliated to French social protection (Primary Health Insurance Fund, CMU, etc.) or European social protection.
- Patient with or having had optic neuropathy regardless of its etiology
- Patient with glaucoma regardless of its etiology;
- Patient not wanting to undergo OCT;
- Patient not wanting to sign the informed consent;
- Patient not affiliated with French social protection (Primary Health Insurance Fund, CMU, etc.) or European.
- Patients less than 18 years old or over 60 years old
- Pregnant patient
The study team makes the final eligibility decision.
Where it's taking place
- Paris, Paris, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Paris, Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.